Anafranil

Panic Disorder, Depression, Obsessive-Compulsive Disorder

Treatment

2 FDA approvals

20 Active Studies for Anafranil

What is Anafranil

Clomipramine

The Generic name of this drug

Treatment Summary

Clomipramine is a type of antidepressant drug used to treat mood disorders such as depression, obsessive-compulsive disorder, and schizophrenia. It is a tricyclic antidepressant (TCA) that works by increasing the levels of serotonin and norepinephrine in the brain. Common side effects of clomipramine include blurred vision, dry mouth, constipation, and urinary retention. It can also be used to treat conditions such as panic disorder, chronic pain, cataplexy, trichotillomania, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine

Anafranil

is the brand name

image of different drug pills on a surface

Anafranil Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Anafranil

Clomipramine

1989

104

Approved as Treatment by the FDA

Clomipramine, also called Anafranil, is approved by the FDA for 2 uses like Obsessive Compulsive Disorder (OCD) and Obsessive-Compulsive Disorder .

Obsessive Compulsive Disorder (OCD)

Helps manage Obsessive Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder

Helps manage Obsessive Compulsive Disorder (OCD)

Effectiveness

How Anafranil Affects Patients

Clomipramine is a type of antidepressant that is believed to work by blocking the reabsorption of certain neurotransmitters, like norepinephrine and serotonin, in the brain. Although this process occurs quickly, it may take up to two weeks for a person to notice an improvement in their mood. It is also thought that clomipramine changes the sensitivity of certain receptors in the brain, which can help with emotions. In addition, clomipramine can help relieve different types of pain, particularly nerve-related pain.

How Anafranil works in the body

Clomipramine works by blocking the reuptake of serotonin and noradrenaline in the brain. It also blocks certain receptors, such as alpha-1 receptors, and reduces the activity of some proteins. These effects help to reduce pain, particularly chronic or neuropathic pain.

When to interrupt dosage

The proposed dosage of Anafranil is contingent upon the determined condition, including Obsessive-Compulsive Disorder, Depression and Panic Disorder. The measure of dosage fluctuates, in accordance with the delivery approach featured in the table below.

Condition

Dosage

Administration

Obsessive-Compulsive Disorder

25.0 mg, , 50.0 mg, 75.0 mg, 10.0 mg, 100.0 mg

Capsule, , Oral, Capsule - Oral, Tablet, Tablet - Oral

Panic Disorder

25.0 mg, , 50.0 mg, 75.0 mg, 10.0 mg, 100.0 mg

Capsule, , Oral, Capsule - Oral, Tablet, Tablet - Oral

Depression

25.0 mg, , 50.0 mg, 75.0 mg, 10.0 mg, 100.0 mg

Capsule, , Oral, Capsule - Oral, Tablet, Tablet - Oral

Warnings

Anafranil Contraindications

Condition

Risk Level

Notes

Myocardial Infarction

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Anafranil.

Common Anafranil Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Anagrelide.

Apixaban

Major

The metabolism of Apixaban can be decreased when combined with Clomipramine.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Asenapine.

Anafranil Toxicity & Overdose Risk

Symptoms of Anafranil overdose can range from minor to severe, depending on how much was taken and the age of the person. Severe reactions can lead to irregular heart rhythms, dangerously low blood pressure, seizures, and loss of consciousness. In the U.S., two people have died from taking too much Anafranil. Common side effects of Anafranil include drowsiness, low blood pressure, blurry vision, dry mouth, constipation, difficulty urinating, standing dizziness, rapid heart rate, high blood pressure, changes in the heart's electrical activity, heart failure, memory problems, confusion and mania

image of a doctor in a lab doing drug, clinical research

Anafranil Novel Uses: Which Conditions Have a Clinical Trial Featuring Anafranil?

634 active clinical trials are underway to assess the potential of Anafranil for treating Panic Disorder, Obsessive-Compulsive Disorder and Depression.

Condition

Clinical Trials

Trial Phases

Obsessive-Compulsive Disorder

66 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1

Panic Disorder

13 Actively Recruiting

Not Applicable

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Anafranil Reviews: What are patients saying about Anafranil?

5

Patient Review

10/9/2013

Anafranil for Obsessive Compulsive Disorder

Within days of starting this medication, I noticed a decrease in my anxiety levels. I no longer felt the need to check and recheck things all the time, which was a huge relief. For me, it was effective at half the starting dose, and I'm only 105 pounds.

5

Patient Review

12/10/2016

Anafranil for Obsessive Compulsive Disorder

When I was first diagnosed with OCD and started taking this medication, it made a huge difference in my life. It helped me manage my symptoms and cravings, and I felt better overall.

5

Patient Review

6/26/2017

Anafranil for Panic Disorder

I used to suffer from panic attacks and emetophobia, but this treatment has really helped me. I'm so much better now and I can live my life without anxiety interfering all the time.

5

Patient Review

12/7/2013

Anafranil for Anxious

Abilify has done wonders for my bipolar disorder. I highly recommend it to anyone who struggles with similar issues.

5

Patient Review

7/1/2013

Anafranil for Obsessive Compulsive Disorder

This drug is WAY more effective for OCD than Zoloft or Luvox. I've also found it helpful for the aches and pains that come along with depression.

5

Patient Review

8/4/2019

Anafranil for Obsessive Compulsive Disorder

Anafranil has been a life-saver for me. I was prescribed several SSRIs and none of them helped with my depression or intrusive thoughts. Within two weeks of taking Anafranil, I stopped crying and it slowly helped with the thoughts as well.

5

Patient Review

4/22/2019

Anafranil for Anxious

This treatment was life-saving.

4.3

Patient Review

2/6/2015

Anafranil for Obsessive Compulsive Disorder

This medication helped me to control my obsessive thoughts and it's been a huge game-changer for me. However, I have unfortunately gained about 40 pounds since starting the treatment. If anyone has any suggestions of how to lose this weight, I would be very grateful!

3.7

Patient Review

10/23/2014

Anafranil for Obsessive Compulsive Disorder

I was on this medication for a long time, but I decided to try something else. Now that I've tapered off of it, I feel pretty bad. Not sure how long these withdrawal symptoms will last.

2.3

Patient Review

4/2/2022

Anafranil for Obsessive Compulsive Disorder

Unfortunately, this medication made my OCD worse. I was dealing with more intrusive thoughts and felt crazy as a result.

1.7

Patient Review

2/8/2014

Anafranil for Obsessive Compulsive Disorder

I've been taking this drug on and off for over 30 years. It always works great, but it can take a couple of months to really kick in. The side effects can be tough to deal with, but it's worth it in the end.

1.3

Patient Review

4/28/2018

Anafranil for Obsessive Compulsive Disorder

Anafranil was decent for depression, but it didn't help my OCD at all. Additionally, I experienced a racing heart while taking it and had to stop because it was really scary. Finally, it made me feel sedated even during the day.

1

Patient Review

3/29/2019

Anafranil for Obsessive Compulsive Disorder

I took this medication for years at various doses and it made me very unstable, nervous and agitated. I would suggest trying Luvox, Zoloft or any other SSRI before taking this one.

1

Patient Review

6/27/2013

Anafranil for Obsessive Compulsive Disorder

Unfortunately, this medication made me very ill. I had a range of negative side effects that were quite unpleasant.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about anafranil

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Anafranil drug used for?

"Anafranil is a drug used to treat symptoms of OCD such as recurrent thoughts or feelings and repetitive actions. It is available in generic form."

Answered by AI

Does Anafranil make you sleepy?

"You may feel tired, dizzy, or drowsy, or have blurred vision when taking Anafranil. Be careful not to drink alcohol or take any pain relievers, sleeping pills, or antihistamines while you're taking this medicine."

Answered by AI

Is Anafranil good for anxiety?

"Clomipramine helps to control obsessive-compulsive disorder by reducing the duration and intensity of the symptoms, as well as the anxiety that accompanies them. It may be just as effective as imipramine for panic attacks."

Answered by AI

Does Anafranil make you gain weight?

"In these studies, more than a quarter of patients who were given Anafranil gained at least seven percent of their body weight, compared to only four percent of those given a placebo. Several patients' weight gain exceeded 25% of their original body weight."

Answered by AI

Clinical Trials for Anafranil

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Have you considered Anafranil clinical trials?

We made a collection of clinical trials featuring Anafranil, we think they might fit your search criteria.
Go to Trials
Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Have you considered Anafranil clinical trials?

We made a collection of clinical trials featuring Anafranil, we think they might fit your search criteria.
Go to Trials
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA

The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.

Waitlist Available
Has No Placebo

University of California San Diego

Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL

This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.

Recruiting
Has No Placebo

Mayo Clinic in Florida

Juan C. Cardenas Rosales, MD

Have you considered Anafranil clinical trials?

We made a collection of clinical trials featuring Anafranil, we think they might fit your search criteria.
Go to Trials